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ECONOMIC AND OUTCOMES ISSUES 
OF CANCER
PCD1
DIRECT AND INDIRECT COSTS OF 
CHEMOTHERAPY-INDUCED TOXICITY
Calhoun E, Fishman D, Roland P, Lurain J, Bennett C
Northwestern University, Chicago, IL, USA
OBJECTIVE: Chemotherapy-induced toxicities (CIT)
may have a significant impact on overall healthcare costs;
however, there is limited research on the total costs asso-
ciated with CIT, particularly indirect costs. The objective
of this prospective study is to assess the cost of neuro-
logic and hematologic toxicities in women with breast
and gynecologic cancers. 
METHODS: Women experiencing CIT completed ques-
tionnaires that assessed healthcare utilization and patient
and caregiver productivity loss. Direct medical costs were
based on hospital cost-accounting data and indirect costs
were based on Labor Force, Employment, and Earnings
data. 
RESULTS: The average time in the study for hematotoxic-
ity was 2.9 months and 5.5 months for the neurotoxicity
group. The mean age for women in the study was 59.5
years with an average household income of $44,702. The
mean direct medical costs for hematotoxicity were $2172
(sd  $2818, range  $0–$9500) and $460 (sd  $1920,
range  $0–$3500) for neurotoxicity. Patient-related indi-
rect costs for hematotoxicity averaged $2778 (sd 
$2627, range  $291–$8791) in lost wages compared to
$12,460 (sd  $8370, range  $169–$23,976) for neuro-
toxicity. Additionally, non-paid caregivers were needed
38% of the time for women with hematotoxicity and
missed work 43.7% of the time for an average of 2.5
hours/week. While women with neurotoxicity required
more help from informal caregivers (53.7%) incurring an
average of 4 hours per week of lost wages. Paid workers
were needed 44.5% (mean  6.75 hours/week) for hema-
totoxicity and 26.8% (mean  3.7 hours/week) for neuro-
toxicity. 
CONCLUSIONS: Chemotherapy-induced hemato- and
neurotoxicities have significant direct and indirect costs.
Neurotoxicity appears to result in a disproportionate
amount of indirect costs due in part to longer duration of
neurotoxicity-related morbidities. Future research on the
costs of CIT should include an assessment of the impact
of indirect costs.
PCD2
COSTS ASSOCIATED WITH 
CHEMOTHERAPY-INDUCED TOXICITIES:
A REVIEW OF THE LITERATURE
Jackson S1, Peeples P1, Hanson-Divers C2
1Alza Corporation, Palo Alto, CA, USA; 2Center for Health 
Information, Chesapeake, VA, USA
Pharmaceutical agents that prevent or manage chemo-
therapy-induced toxicity (CIT) have recently become
available, and the impact of their overall healthcare cost
savings is ill defined. 
OBJECTIVE: The purpose of this review is to evaluate
the overall cost associated with CITs, particularly cardio-
vascular toxicities, hematologic toxicities, neurotoxici-
ties, and nephrotoxicities. 
METHODS: A comprehensive review of the literature was
conducted to identify studies that reported CIT-associated
costs, either as a primary or secondary study endpoint.
The diversity of this therapeutic area necessitated these ex-
clusion criteria: cancers secondary to autoimmune defi-
ciencies, chemotherapy following transplantation or radia-
tion treatment, and studies restricted to hypothetical costs
or to chemotherapy-related nausea and vomiting. Inclu-
sion criteria comprised chemically induced (or adverse
event) toxicities and cost-related measures. 
RESULTS: Definitions and methods used by researchers
measuring CIT-associated costs vary widely. Most studies
included only direct medical costs, with emphasis on inpa-
tient resource utilization. Thus, hospitalization consis-
tently was identified as the most important factor affecting
total costs, regardless of cancer type. As a percentage of to-
tal treatment costs, CIT costs comprised up to 58% of all
resources expended on inpatient cancer care. Toxicity cost
estimates ranged as follows: febrile neutropenia, $250–
$9000; cardiotoxicity, $1700–$5600; thrombocytopenia,
$1000–$2600. No study has evaluated nephrotoxicity and
neurotoxicity costs. 
CONCLUSIONS: Overall, costs associated with CITs may
be substantial. Both direct and indirect costs, costs associ-
ated with chemotherapy-induced neutropenia and nephro-
toxicity, and costs associated with ambulatory care or
with toxicities occurring beyond the initial chemotherapy
regimen need to be elucidated. A comprehensive, prospec-
tive cost-of-illness study that examines overall costs associ-
ated with CITs would help determine how to best use fi-
nite healthcare dollars to improve patient care.
PCD3
COSTS AND OUTCOMES OF HOME 
VERSUS HOSPITAL-BASED TREATMENT OF 
FEBRILE NEUTROPENIA IN PEDIATRIC 
ONCOLOGY PATIENTS
Raisch DW 1,2, Holdsworth MT2, Winter SS2, Hutter JJ3, 
Graham ML3
1VA Cooperative Studies Program Clinical Research 
Pharmacy, Albuquerque, NM, USA; 2University of New 
Mexico, Albuquerque, NM, USA; 3University of Arizona, 
Tucson, AZ, USA
OBJECTIVE: We compared costs and outcomes associ-
ated with home and hospital-based treatment of febrile
neutropenia (FN) among pediatric oncology patients. 
METHODS: In a historical case series study we gathered
data from charts of University of New Mexico (UNM)
patients who were treated at home (n  36, 72 treat-
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ments) and University of Arizona (UA) patients who were
treated in the hospital (n  27, 72 treatments). All
healthcare resources and treatment outcomes were ob-
tained for each episode of FN. Uniform charge values
were applied to each healthcare resource. Outcome data
included positive blood cultures and days to resolution of
FN, based upon fever and absolute neutrophil count. We
applied Mann-Whitney U and chi square tests. Sensitivity
analyses were performed using charges per episode. 
RESULTS: Both groups were similar for gender, age, types
of diseases, and FN-inducing chemotherapies. More of the
home-treated patients were treated with granulocyte colony
stimulating factor (58 versus 42, p  0.004). The median
total estimated charge per episode was $9166 for UA pa-
tients versus $5117 for UNM patients (p  0.001). Lower
charges for UNM patients, included hospital days, microbi-
ology cultures, blood counts, serum chemistries, physician
visits, radiologic studies, and serum antibiotic levels. Posi-
tive blood cultures occurred more frequently in UA patients
(30.6% versus 11.1%, p  0.012) and mean days to reso-
lution of FN was 8.6 versus 7.6 for UNM patients (NS).
Results were stable across all sensitivity analyses. 
CONCLUSION: With careful supervision by a pediatric
oncology center, uncomplicated FN can be treated by
home care, with substantial savings.
PCD4
THE VALUE OF HOME CARE IN METASTATIC 
BREAST CANCER MANAGEMENT: MODELING 
ORAL VERSUS INTRAVENOUS CHEMOTHERAPY 
AT HOME AND AT AN OUTPATIENT CLINIC
Mathes A, Hay J
University of Southern California, Los Angeles, CA, USA
Few studies have investigated the cost-effectiveness of
oral chemotherapeutic agents that are used to treat meta-
static breast cancer (MBC) at home and in clinic settings. 
OBJECTIVE: This study assessed the value of MBC man-
agement using intravenous (IV) and oral chemotherapeu-
tic agents. 
METHODS: A predictive data collection approach
(modeling) was used to perform this cost-effectiveness
analysis. Data were used from existing economic com-
parisons between home care and clinic care, from clinical
trials, and using Medicare cost data in 1998 US dollars.
A societal perspective was used to compare the cost-effec-
tiveness of the following first-line chemotherapy regi-
mens: C*MF (oral cyclophosphamide [C*], IV metho-
trexate [M], IV fluoruracil [F]), and AC (IV doxorubicin
[A] and IV cyclophosphamide) at home and at an outpa-
tient clinic; and the second-line regimens: IV paclitaxel
(P), oral etoposide (E*), oral idarubicin (I*), and oral
UFT (U*) at home and at an outpatient clinic. 
RESULTS: C*MF, administered at home, was the most
cost-effective first-line strategy (34,163 $/QALY). The
home AC regimen was more costly, and more effective. It
was not, however, cost-effective relative to the home
C*MF strategy because the incremental cost-effectiveness
(ICE) between the two strategies was 1,763,990 $/QALY.
E*, administered at home, was found to be the most cost-
effective second-line strategy (33,789 $/QALY). Other
strategies (home P, clinic I*, and home I*) were more
costly, but more effective. These strategies, however, were
not cost-effective relative to home E* because the ICE be-
tween these strategies and E* were 945,101 $/QALY,
369,232 $/QALY, and 175,523 $/QALY, respectively. 
CONCLUSIONS: These results suggest that oral chemo-
therapeutic agents, administered at home, provide a cost-
effective means of treating MBC.
PCD5
RELIABILITY AND VALIDITY OF THE BREAST 
EVALUATION QUESTIONNAIRE (BEQ): 
AN OUTCOME MEASURE FOR BREAST
IMPLANT STUDIES
Lenderking WR, Tafesse E
Abt Associates Clinical Trials, Cambridge, MA, USA
OBJECTIVE: This study was undertaken to determine the
optimal scoring for the Breast Evaluation Questionnaire
(BEQ), and to provide evidence for its validity as a mea-
sure of comfort and satisfaction for women undergoing
breast augmentation for cosmetic reasons. The BEQ is a
55-item questionnaire. A 76-item version was previously
validated in a sample of undergraduate women (non-clini-
cal sample). The BEQ measures satisfaction with breast at-
tributes, and comfort with general appearance and appear-
ance of breasts while fully dressed, in a bathing suit, and
while naked, across a variety of situations. 
METHODS: We conducted exploratory factor analysis in
1244 women at baseline prior to the augmentation proce-
dure. We conducted analysis of reliability of the factors, ex-
amined discriminant validity of the items of the BEQ, and
examined associations between the BEQ factors and widely
used measures of self-esteem and body-self relations. 
RESULTS: The factor analysis indicated that the BEQ is op-
timally scored as three factors: Comfort Not Fully Dressed,
Comfort Fully Dressed, and Satisfaction with Breast At-
tributes. These factors form internally consistent subscales,
which remain reliable over time (Cronbach’s  minimum
value across four visits was .89 for all three factors). We
demonstrated that the items have discriminant validity. The
factors are moderately correlated with the Appearance Eval-
uation subscale of the Multi-Dimensional Body Self Rela-
tions Questionnaire (MBSRQ) and the Physical Self sub-
scale of the Tennessee Self-Concept Scale (TSC). 
CONCLUSIONS: The BEQ can now be scored with
greater simplicity and greater ease of interpretation than
was previously indicated.
PCD6
COMPARISON OF THE McMASTER’S HEALTH 
UTILITIES INDEX-MARK III AND THE
EUROQOL-5D IN A SURGICAL BREAST
CANCER POPULATION
